{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:34:17Z","timestamp":1761489257946},"reference-count":15,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T00:00:00Z","timestamp":1384387200000},"content-version":"vor","delay-in-days":2662,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microbiology and Immunology"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The mycobacterial activities of cinamyl rifamycin derivatives, T\u20109 and T\u201011, especially against extracellular and intracellular <jats:italic>Mycobacterium avium<\/jats:italic> complex residing within macrophages and type II pneumocytes were compared with those of other rifamycins. The activities of test rifamycins were found to be in the order rifalazil, rifabutin, T\u20109, T\u201011, and rifampicin.<\/jats:p>","DOI":"10.1111\/j.1348-0421.2006.tb03836.x","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T14:19:26Z","timestamp":1384438766000},"page":"621-623","source":"Crossref","is-referenced-by-count":3,"title":["Antimicrobial Activities of Cinnamyl Rifamycin Derivatives, T\u20109 and T\u201011, against <i>Mycobacterium tuberculosis<\/i> and <i>Mycobacterium avium<\/i> Complex (MAC) with Special Reference to the Activities against Intracellular MAC"],"prefix":"10.1111","volume":"50","author":[{"given":"Katsumasa","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology Shimane University School of Medicine  Izumo Shimane 693\u20108501 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology Shimane University School of Medicine  Izumo Shimane 693\u20108501 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Velitchka","family":"Dimova","sequence":"additional","affiliation":[{"name":"National Center of Infectious and Parasitic Diseases  Sofia Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruaki","family":"Tomioka","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology Shimane University School of Medicine  Izumo Shimane 693\u20108501 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,11,14]]},"reference":[{"key":"e_1_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612043383197"},{"key":"e_1_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612043383214"},{"key":"e_1_2_2_4_1","first-page":"1","volume-title":"Incentives and disincentives for new anti\u2010tuberculous drug development. Situational analysis","author":"Blanc D.C.","year":"2000"},{"key":"e_1_2_2_5_1","first-page":"61","article-title":"The rationale for recommending fixed\u2010dose combination tablets for treatment of tuberculosis","volume":"79","author":"Blomberg B.","year":"2001","journal-title":"Bull. World Health Organ."},{"key":"e_1_2_2_6_1","unstructured":"Dimova V. Stefanova P. andValova N.1993.Pharmacokinetic studies in experimental animals on cinamyl rifamycin derivative (T\u20109) p.351\u2013352.InAdvances in chemotherapy Proceedings of the 17th International Congress of Chemotherapy Stockholm."},{"key":"e_1_2_2_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.10.2320"},{"key":"e_1_2_2_8_1","first-page":"651","article-title":"Tuberculosis treatment for the beginning of the next century","volume":"3","author":"Schraufnagel D.E.","year":"1999","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_2_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199528020-00003"},{"key":"e_1_2_2_10_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18450"},{"key":"e_1_2_2_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570163043334811"},{"key":"e_1_2_2_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/1567269054867022"},{"key":"e_1_2_2_13_1","doi-asserted-by":"crossref","unstructured":"Tomioka H.2006.Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to theirin vitroandin vivoantimicrobial activities.Curr. Pharm. Des.in press.","DOI":"10.2174\/138161206778743646"},{"key":"e_1_2_2_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.519-521.2002"},{"key":"e_1_2_2_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-004-4001-4"},{"key":"e_1_2_2_16_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.41.148"}],"container-title":["Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1348-0421.2006.tb03836.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1348-0421.2006.tb03836.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T22:04:40Z","timestamp":1700517880000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1348-0421.2006.tb03836.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1111\/j.1348-0421.2006.tb03836.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1348-0421.2006.tb03836.x","archive":["Portico"],"relation":{},"ISSN":["0385-5600","1348-0421"],"issn-type":[{"value":"0385-5600","type":"print"},{"value":"1348-0421","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}